Cargando…

Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge

Layer-by-layer microparticle (LbL-MP) fabrication was used to produce synthetic vaccines presenting a fusion peptide containing RSV G protein CX3C chemokine motif and a CD8 epitope of the RSV matrix protein 2 (GM2) with or without a covalently linked TLR2 agonist (Pam3.GM2). Immunization of BALB/c m...

Descripción completa

Detalles Bibliográficos
Autores principales: Powell, Thomas J., Jacobs, Andrea, Tang, Jie, Cardenas, Edwin, Palath, Naveen, Daniels, Jennifer, Boyd, James G., Bergeron, Harrison C., Jorquera, Patricia A., Tripp, Ralph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785538/
https://www.ncbi.nlm.nih.gov/pubmed/36560488
http://dx.doi.org/10.3390/vaccines10122078
_version_ 1784858073184075776
author Powell, Thomas J.
Jacobs, Andrea
Tang, Jie
Cardenas, Edwin
Palath, Naveen
Daniels, Jennifer
Boyd, James G.
Bergeron, Harrison C.
Jorquera, Patricia A.
Tripp, Ralph A.
author_facet Powell, Thomas J.
Jacobs, Andrea
Tang, Jie
Cardenas, Edwin
Palath, Naveen
Daniels, Jennifer
Boyd, James G.
Bergeron, Harrison C.
Jorquera, Patricia A.
Tripp, Ralph A.
author_sort Powell, Thomas J.
collection PubMed
description Layer-by-layer microparticle (LbL-MP) fabrication was used to produce synthetic vaccines presenting a fusion peptide containing RSV G protein CX3C chemokine motif and a CD8 epitope of the RSV matrix protein 2 (GM2) with or without a covalently linked TLR2 agonist (Pam3.GM2). Immunization of BALB/c mice with either GM2 or Pam3.GM2 LbL-MP in the absence of adjuvant elicited G-specific antibody responses and M2-specific CD8+ T-cell responses. Following challenge with RSV, mice immunized with the GM2 LbL-MP vaccine developed a Th2-biased immune response in the lungs with elevated levels of IL-4, IL-5, IL-13, and eotaxin in the bronchoalveolar lavage (BAL) fluid and a pulmonary influx of eosinophils. By comparison, mice immunized with the Pam3.GM2 LbL-MP vaccine had considerably lower to non-detectable levels of the Th2 cytokines and chemokines and very low numbers of eosinophils in the BAL fluid post-RSV challenge. In addition, mice immunized with the Pam3.GM2 LbL-MP also had higher levels of RSV G-specific IgG2a and IgG2b in the post-challenge BAL fluid compared to those immunized with the GM2 LbL-MP vaccine. While both candidates protected mice from infection following challenge, as evidenced by the reduction or elimination of RSV plaques, the inclusion of the TLR2 agonist yielded a more potent antibody response, greater protection, and a clear shift away from Th2/eosinophil responses. Since the failure of formalin-inactivated RSV (FI-RSV) vaccines tested in the 1960s has been hypothesized to be partly due to the ablation of host TLR engagement by the vaccine and inappropriate Th2 responses upon subsequent viral infection, these findings stress the importance of appropriate engagement of the innate immune response during initial exposure to RSV G CX3C.
format Online
Article
Text
id pubmed-9785538
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97855382022-12-24 Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge Powell, Thomas J. Jacobs, Andrea Tang, Jie Cardenas, Edwin Palath, Naveen Daniels, Jennifer Boyd, James G. Bergeron, Harrison C. Jorquera, Patricia A. Tripp, Ralph A. Vaccines (Basel) Article Layer-by-layer microparticle (LbL-MP) fabrication was used to produce synthetic vaccines presenting a fusion peptide containing RSV G protein CX3C chemokine motif and a CD8 epitope of the RSV matrix protein 2 (GM2) with or without a covalently linked TLR2 agonist (Pam3.GM2). Immunization of BALB/c mice with either GM2 or Pam3.GM2 LbL-MP in the absence of adjuvant elicited G-specific antibody responses and M2-specific CD8+ T-cell responses. Following challenge with RSV, mice immunized with the GM2 LbL-MP vaccine developed a Th2-biased immune response in the lungs with elevated levels of IL-4, IL-5, IL-13, and eotaxin in the bronchoalveolar lavage (BAL) fluid and a pulmonary influx of eosinophils. By comparison, mice immunized with the Pam3.GM2 LbL-MP vaccine had considerably lower to non-detectable levels of the Th2 cytokines and chemokines and very low numbers of eosinophils in the BAL fluid post-RSV challenge. In addition, mice immunized with the Pam3.GM2 LbL-MP also had higher levels of RSV G-specific IgG2a and IgG2b in the post-challenge BAL fluid compared to those immunized with the GM2 LbL-MP vaccine. While both candidates protected mice from infection following challenge, as evidenced by the reduction or elimination of RSV plaques, the inclusion of the TLR2 agonist yielded a more potent antibody response, greater protection, and a clear shift away from Th2/eosinophil responses. Since the failure of formalin-inactivated RSV (FI-RSV) vaccines tested in the 1960s has been hypothesized to be partly due to the ablation of host TLR engagement by the vaccine and inappropriate Th2 responses upon subsequent viral infection, these findings stress the importance of appropriate engagement of the innate immune response during initial exposure to RSV G CX3C. MDPI 2022-12-05 /pmc/articles/PMC9785538/ /pubmed/36560488 http://dx.doi.org/10.3390/vaccines10122078 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Powell, Thomas J.
Jacobs, Andrea
Tang, Jie
Cardenas, Edwin
Palath, Naveen
Daniels, Jennifer
Boyd, James G.
Bergeron, Harrison C.
Jorquera, Patricia A.
Tripp, Ralph A.
Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge
title Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge
title_full Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge
title_fullStr Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge
title_full_unstemmed Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge
title_short Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge
title_sort microparticle rsv vaccines presenting the g protein cx3c chemokine motif in the context of tlr signaling induce protective th1 immune responses and prevent pulmonary eosinophilia post-challenge
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785538/
https://www.ncbi.nlm.nih.gov/pubmed/36560488
http://dx.doi.org/10.3390/vaccines10122078
work_keys_str_mv AT powellthomasj microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge
AT jacobsandrea microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge
AT tangjie microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge
AT cardenasedwin microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge
AT palathnaveen microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge
AT danielsjennifer microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge
AT boydjamesg microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge
AT bergeronharrisonc microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge
AT jorquerapatriciaa microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge
AT trippralpha microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge